![]() |
市場調查報告書
商品編碼
1933385
全球體外診斷(IVD)合約製造市場:市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測(2026-2034)IVD Contract Manufacturing Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034 |
||||||
全球體外診斷(IVD)合約製造市場規模預計在2025年將達到196.6億美元,2026年將成長至207.4億美元,到2034年將達到372.3億美元,預測期內複合年增長率(CAGR)為7.59%。北美地區憑藉其先進的醫療保健基礎設施、慢性病高發生率以及醫療器材製造商強勁的外包趨勢,在2025年佔市場主導地位,市場佔有率達36.26%。
體外診斷(IVD)合約製造是指將診斷設備的設計、開發和生產外包給專業的第三方製造商。 慢性疾病(例如傳染病、糖尿病和心血管疾病)的日益流行推動了體外診斷 (IVD) 檢測的需求,並為合約製造商創造了機會。此外,診斷設備(包括多重檢測)的日益複雜化,也加速了生產外包給專業 IVD 合約製造商(例如 Thermo Fisher Scientific、Nova Biomedical 和 Argonaut Manufacturing Services)的趨勢。
市場動態
市場驅動因素
對 IVD 診斷測試的需求不斷增長
日益加重的疾病負擔,加上早期檢測意識的提高,正在推動全球診斷檢測量的成長。例如,根據國際糖尿病聯盟 (IDF) 2024 年的報告,全球約有 5.89 億成年人將患有糖尿病。這種不斷增長的診斷需求促使原始設備製造商 (OEM) 更加依賴合約製造商進行快速、高品質的生產,從而推動了 IVD 合約製造市場的成長。
市場限制
智慧財產權 (IP) 問題
與合約製造商分享機密資訊(例如檢測配方、試劑組成和軟體程式碼)會為原始設備製造商 (OEM) 帶來潛在的智慧財產權風險。除了這些問題之外,智慧財產權執法方面的區域差異也限制了外包。根據 2025 年版的 "HIPAA Journal" ,41.2% 的第三方資料外洩事件影響了醫療機構,凸顯了合約製造中存在的保密性挑戰。
市場機會
新興經濟體的擴張
印度、巴西和墨西哥等新興市場在醫療保健成本上升、疾病篩檢計畫和政府主導的措施的推動下,蘊藏著巨大的成長機會。預計到 2025 年,印度的生產關聯激勵 (PLI) 計劃將促進診斷產品的國內生產,從而提振體外診斷 (IVD) 合約製造的需求。 此外,精準診斷、個人化醫療、微流控和分子診斷領域的進步,正為專業合約製造合作夥伴關係創造長期成長機會。
市場挑戰
嚴格的監理要求
各地監管框架的差異和監管能力的不足,為全球合約製造商帶來了許多障礙。例如,截至2024年,歐洲僅有12家根據體外診斷醫療器材法規 (IVDR) 獲得認證的機構,而先前的指令下則有22家,這使得原始設備製造商 (OEM) 的合規性更加複雜,並限制了市場接受度。高昂的初始投資要求以及對關鍵原料供應商的依賴,也為中小型製造商帶來了挑戰。
市場趨勢
體外診斷製造領域的技術進步
自動化、機器人、數位化和人工智慧工具的整合正在改變合約製造業。這些技術提高了精度、可重複性、可擴展性和合規性。 例如,根據梅奧診所 2025 年報告,超過 50% 的病理病例已數位化,並透過數位平台進行分析,這表明診斷領域對技術的應用日益廣泛。此外,即時檢測解決方案、分子診斷和合作關係正在重塑體外診斷 (IVD) 製造生態系統。
依產品類型
市場分為儀器和耗材兩部分。耗材部分佔市場主導地位,預計到 2026 年將達到 66.96% 的市場佔有率,這主要得益於全球診斷測試數量的增加以及測試盒等產品的批准。
依科技
市場分為免疫診斷、臨床化學、分子診斷、血液學和其他技術。 2025年,免疫診斷領域將引領市場,預計到2026年將維持34%的市場佔有率,這主要得益於慢性病和傳染病患病率的上升。分子診斷預計將以7.4%的複合年增長率成長。
依服務類型劃分
預計到2026年,製造業服務領域將以71.98%的市佔率引領市場,這主要得益於慢性病診斷需求的成長以及新設施的建立,例如SCIENION於2022年新建的ISO5級無塵室。檢測開發服務預計將以7.5%的複合年增長率成長。
依最終使用者劃分
醫療器材製造商將在2025年主導市場,並由於檢測量和醫療器材製造商數量的增加,在2026年佔60.22%的市場佔有率。 預計製藥和生技公司將以 7.5% 的複合年增長率成長。
預計北美將引領市場,2025 年市場規模將達到 71.3 億美元,到 2026 年將達到 75.5 億美元。其中,美國預計將佔 64.2 億美元。 預計到2025年,歐洲市場規模將達到61.6億美元,其中英國、德國和法國在2026年分別將達到10.4億美元、14.1億美元和11.8億美元。預計到2025年,亞太地區市場規模將達到41.1億美元,其中印度和中國在2026年將分別達到6.6億美元和14.3億美元。拉丁美洲市場規模預計到2025年將達到15億美元,中東和非洲的海灣合作委員會(GCC)地區市場規模預計到2025年將達到4.2億美元。
The global IVD (In Vitro Diagnostic) contract manufacturing market was valued at USD 19.66 billion in 2025 and is projected to grow to USD 20.74 billion in 2026, eventually reaching USD 37.23 billion by 2034, exhibiting a CAGR of 7.59% during the forecast period. North America dominated the market in 2025 with a 36.26% share, owing to advanced healthcare infrastructure, high prevalence of chronic diseases, and strong outsourcing trends among medical device companies.
IVD contract manufacturing involves outsourcing the design, development, and production of diagnostic devices to specialized third-party manufacturers. The rising prevalence of chronic conditions such as infectious diseases, diabetes, and cardiovascular disorders has fueled the demand for IVD testing, creating opportunities for contract manufacturers. Moreover, the increasing complexity of diagnostic devices, including multiplex assays, has accelerated the preference for outsourcing production to specialized IVD contract manufacturers such as Thermo Fisher Scientific Inc., Nova Biomedical, and Argonaut Manufacturing Services Inc.
Market Dynamics
Market Drivers
Rising Demand for IVD Diagnostics
The growing disease burden, coupled with awareness campaigns for early detection, is driving the number of diagnostic tests globally. For instance, the International Diabetes Federation reported in 2024 that around 589 million adults live with diabetes worldwide. This increasing diagnostic demand pushes original equipment manufacturers (OEMs) to rely on contract manufacturers for timely and quality production, thereby boosting the IVD contract manufacturing market.
Market Restraints
Intellectual Property (IP) Concerns
Sharing sensitive information, such as assay formulations, reagent compositions, and software codes with contract manufacturers, exposes OEMs to potential IP risks. This concern, coupled with varying IP enforcement across regions, limits outsourcing. According to The HIPAA Journal 2025, 41.2% of third-party data breaches affect healthcare organizations, highlighting the challenges of maintaining confidentiality in contract manufacturing.
Market Opportunities
Expansion in Emerging Economies
Emerging markets like India, Brazil, and Mexico present significant growth potential due to increased healthcare spending, disease screening programs, and governmental initiatives. In 2025, India's Production-Linked Incentive (PLI) scheme encourages domestic manufacturing of diagnostic products, boosting IVD contract manufacturing demand. Additionally, precision diagnostics, personalized medicine, and advancements in microfluidics and molecular diagnostics are creating long-term opportunities for specialized contract manufacturing partnerships.
Market Challenges
Stringent Regulatory Requirements
Distinct regulatory frameworks across geographies and limited review capacities create hurdles for global contract manufacturers. For instance, Europe has only 12 notified bodies under IVDR in 2024, compared to 22 under previous directives, making compliance complex for OEMs and limiting market adoption. High initial investment requirements and dependence on key raw material suppliers also pose challenges for smaller manufacturers.
Market Trends
Technological Advancements in IVD Manufacturing
Integration of automation, robotics, digitization, and AI tools is reshaping contract manufacturing. These technologies enhance precision, reproducibility, scalability, and regulatory compliance. For example, Mayo Clinic 2025 reported that over 50% of pathology cases were digitized and analyzed through digital platforms, indicating a growing adoption of technology in diagnostics. Additionally, point-of-care testing solutions, molecular diagnostics, and collaborative partnerships are reshaping the IVD manufacturing ecosystem.
By Product Type
The market is divided into instruments and consumables. The consumables segment dominated in 2026 with 66.96% share, driven by the increasing number of diagnostic tests globally and product approvals for items such as test cartridges.
By Technology
Segmented into immunodiagnostics, clinical chemistry, molecular diagnostics, hematology, and others, the immunodiagnostics segment dominated in 2025 and is projected to hold 34% share in 2026, due to rising prevalence of chronic and infectious diseases. Molecular diagnostics is projected to grow at a CAGR of 7.4%.
By Service Type
The manufacturing services segment led the market with 71.98% share in 2026, attributed to growing demand for chronic disease diagnostics and the establishment of new facilities, such as SCIENION's ISO5 cleanrooms in 2022. Assay development services are expected to grow at 7.5% CAGR.
By End User
Medical device companies dominated in 2025, with a projected 60.22% share in 2026, due to increased test volumes and the growing number of medical device companies. Pharmaceutical and biotechnology companies are expected to grow at a CAGR of 7.5%.
North America led the market in 2025 at USD 7.13 billion, and is projected at USD 7.55 billion in 2026, with the U.S. estimated at USD 6.42 billion. Europe reached USD 6.16 billion in 2025, with the U.K., Germany, and France holding USD 1.04 billion, 1.41 billion, and 1.18 billion in 2026, respectively. Asia Pacific was valued at USD 4.11 billion in 2025, with India and China at USD 0.66 billion and 1.43 billion in 2026. Latin America reached USD 1.50 billion in 2025, while GCC in the Middle East & Africa reached USD 0.42 billion in 2025.
Competitive Landscape
Key players include Thermo Fisher Scientific Inc., Argonaut Manufacturing Services Inc., IVD Technologies, Bio-Techne, Invetech, Merck KGaA, Fujirebio, and Celestica Inc. These companies focus on strategic collaborations, facility expansions, and product portfolio enhancements to maintain market dominance. Notable developments include Argonaut Manufacturing Services collaborating with Akoya Biosciences in January 2025, and T&D Diagnostics partnering with Genenest in April 2025 to expand manufacturing in India.
Conclusion
The global IVD contract manufacturing market is poised to grow from USD 20.74 billion in 2026 to USD 37.23 billion by 2034, driven by rising chronic disease prevalence, increasing demand for diagnostic tests, technological integration, and strategic partnerships. North America continues to dominate, while emerging markets in Asia Pacific and Latin America offer lucrative growth opportunities. Despite regulatory complexities and IP concerns, advancements in automation, molecular diagnostics, and point-of-care testing are expected to sustain the market's growth trajectory through 2034.
Segmentation By Product Type, Technology, Service Type, End User, and Region
By Product Type * Instruments
By Technology * Immunodiagnostics
By Service Type * Manufacturing Services
By End User * Medical Device Companies
By Region * North America (By Product Type, By Technology, By Service Type, By End User, and by Country)